Drug Safety Matters
Загальна тривалість:
22 h 17 min
#46 Protecting the health ecosystem – Valentina Giunchi & Joe Mitchell
Drug Safety Matters
35:04
#45 How to perform better disproportionality analyses – Michele Fusaroli & Eugene van Puijenbroek
Drug Safety Matters
47:20
#44 Rethinking medical device safety, part 2 – Omar Aimer
Drug Safety Matters
21:22
#43 Rethinking medical device safety, part 1 – Omar Aimer
Drug Safety Matters
22:44
#42 Unpacking the WHO Global Smart Pharmacovigilance Strategy – Shanthi Pal
Drug Safety Matters
18:43
#41 How to use artificial intelligence in pharmacovigilance, part 2 – Niklas Norén
Drug Safety Matters
29:48
#40 How to use artificial intelligence in pharmacovigilance, part 1 – Niklas Norén
Drug Safety Matters
29:40
#39 Putting children first on Patient Safety Day – Angela Caro-Rojas
Drug Safety Matters
26:16
#38 Patient perspectives in PV: a fireside chat at the ISoP mid-year symposium
Drug Safety Matters
35:23
#37 Beyond numbers: quality in ADR reporting – Henry Zakumumpa
Drug Safety Matters
39:28
#36 Pregnancy-related pharmacovigilance – Levente Pápai, Lovisa Sandberg & Sara Vidlin
Drug Safety Matters
37:23
#35 Veterinary pharmacovigilance, part 2 – James Mount
Drug Safety Matters
42:21
#34 Veterinary pharmacovigilance, part 1 – James Mount
Drug Safety Matters
48:00
#33 Narrative fields and signal assessors, an exploratory study – Joana Félix and Alem Zekarias
Drug Safety Matters
39:22
#32 Pharmacovigilance in older adults – Giovanni Furlan
Drug Safety Matters
48:30
#31 A guide to reporting disproportionality analyses – Michele Fusaroli and Daniele Sartori
Drug Safety Matters
43:24
Uppsala Reports Long Reads – Weeding out duplicates to better detect side effects
Drug Safety Matters
25:42
Uppsala Reports Long Reads – Ensuring trust in AI/ML when used in pharmacovigilance
Drug Safety Matters
30:57
#30 Preventing and reporting medication errors – Rabat CC & UMC
Drug Safety Matters
34:37
#29 When medicines change our behaviour – Michele Fusaroli
Drug Safety Matters
31:09
#28 Catching black swans – François Montastruc
Drug Safety Matters
28:00
#27 When drugs damage the liver – Rita Baião
Drug Safety Matters
29:09
#26 What's trending in pharmacovigilance? – Angela Caro-Rojas
Drug Safety Matters
28:45
#25 A week in the name of medicines safety – part 2
Drug Safety Matters
33:52
#24 A week in the name of medicines safety – part 1
Drug Safety Matters
27:48
Uppsala Reports Long Reads – The colour of signals
Drug Safety Matters
34:38
Uppsala Reports Long Reads – Empowering patients as partners
Drug Safety Matters
43:22
#23 Assessing safety in clinical trials – Marianne Lunzer & Sanja Prpić
Drug Safety Matters
31:45
#22 Reforming pharmacovigilance education – Michael Reumerman
Drug Safety Matters
33:33
#21 Unlocking the power of real-world data – Patrick Ryan
Drug Safety Matters
34:21
#20 The evidence for signals – Daniele Sartori
Drug Safety Matters
46:20
Uppsala Reports Long Reads – Unmasking data in the COVID-19 vaccine era
Drug Safety Matters
21:59
#19 Lessons in pandemic pharmacovigilance – Elena Rocca
Drug Safety Matters
33:51
#18 The IDMP standards explained – Malin Fladvad & Olle Lagerlund
Drug Safety Matters
23:45
#17 Why we need vaccine surveillance systems – Madhava Balakrishnan
Drug Safety Matters
28:09
#16 How drug safety can help fight resistant bugs – Jean Marie Vianney Habarugira & Albert Figueras
Drug Safety Matters
34:21
#15 Safety of HIV medications – Henry Zakumumpa
Drug Safety Matters
33:58
#14 Advancing pharmacovigilance in Africa – Eleni Aklillu & Abbie Barry
Drug Safety Matters
37:59
#13 How to talk about risks – Alexandra Freeman
Drug Safety Matters
38:55
Uppsala Reports Long Reads – Safety issues faced by refugee communities
Drug Safety Matters
25:47
